Investor Type | Firm |
Industries | BioTech • HealthTech (& Fitness) • Medical Devices (& Hospital Services) • Healthcare (& Wellness) • Pharmaceutical (& Medicine) |
Stages | Seed, Series A, Series B, Pre-seed |
Investing | United States |
Investment Range | $100,000 - $5,000,000 |
Investment Sweet Spot | $1,500,000 |
Amzak Health Investors is a venture capital firm focused on funding innovation in the life sciences sector. With a commitment to investing in first-in-class and best-in-class technologies, the firm's investment strategy targets medtech and biotech companies that demonstrate the potential to lead their respective fields. They serve as more than just a financial resource; they partner with their portfolio companies, collaborating with management teams to drive success. Specializing in early-stage investments, their portfolio includes positions in Seed, Series A, and Series B funding rounds, with capacities for Pre-seed investments as well. Amzak Health Investors' expertise spans a range of medical and healthcare industries including BioTech, HealthTech (& Fitness), Medical Devices (& Hospital Services), Healthcare (& Wellness), and Pharmaceutical (& Medicine). The firm is distinguished by a small, yet highly experienced team of investors with extensive backgrounds in investing and operating within the biotech and medtech spheres, boasting a proven track record of successful ventures. Their financial commitment is demonstrated by a minimum investment of $100,000 and a maximum of $5,000,000, with a sweet spot investment of $1,500,000. Amzak Health Investors' approach is characterized by active engagement, striving to make a difference through their investments, as evidenced by their growing portfolio which includes companies like Sound Blade Medical, HistoSonics, and Ginseyonics. These companies are leading innovation with non-invasive medical technologies, such as handheld ultrasound-guided histotripsy and intrauterine fibroid ablation systems, signaling Amzak's hands-on involvement in advancing medical technology and improving patient outcomes.